Skip to main content
. Author manuscript; available in PMC: 2023 Mar 14.
Published in final edited form as: Paediatr Drugs. 2022 Mar 14;24(2):163–173. doi: 10.1007/s40272-022-00493-3

Figure 3. Probabilities of Target Attainment.

Figure 3.

Based on Monte Carlo simulations of the intravenous dosage regimens administered in the study. PK-PD targets used: fAUC/MIC ≥34 for S. pneumoniae and fAUC/MIC ≥75 for Gram-negative bacteria.

fAUC/MIC, area under the free concentration-time curve in a 24-hour interval/minimum inhibitory concentration; PK-PD, pharmacokinetic-pharmacodynamic